These observations provide pre-clinical evidence supporting the use of combination MAPK inhibitors and immunotherapy in BRAFV600 mutated melanoma although the first clinical trial combining anti-CTLA4 and BRAF inhibitor resulted in highly severe hepatotoxicity [95]. The gene discussed is CTLA4; the disease is melanoma.